Clinical Trial Update: Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee [Phase 3]

View source ↗

Summary

Phase 3 randomized study assessing a single dose of Synvisc-One for symptomatic knee osteoarthritis in Chinese patients completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis of the Knee

Drugs mentioned

• Synvisc-One (hylan G-F 20)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Osteoarthritis | Phase 3 | Status: COMPLETED | Results posted: 2020-02-05